Skip to main content
Journal cover image

Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.

Publication ,  Journal Article
Greenbaum, AB; Harrington, RA; Hudson, MP; MacAulay, CM; Wilcox, RG; Simoons, ML; Berdan, LG; Guerci, A; Cokkinos, DV; Kitt, MM; Lincoff, AM ...
Published in: J Am Coll Cardiol
February 2001

OBJECTIVES: We aimed to evaluate the benefits of the glycoprotein (GP) IIb/IIIa antagonist, eptifibatide, after patients with acute coronary syndromes (ACS) were admitted to hospitals that approach revascularization for ACS through early transfer to tertiary referral centers. BACKGROUND: Across a variety of hospital settings, GP IIb/IIIa inhibition, after patients were admitted to the hospital for non-ST segment elevation ACS, is associated with a reduction in death or myocardial infarction (MI) before and during a percutaneous coronary intervention. METHODS: The outcomes of 429 patients from 153 sites in the Platelet glycoprotein IIb/IIIa in unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, who were transferred during study drug infusion ("transfer patients"), were compared with those of 1,987 patients who either remained in the hospital at those sites or were transferred after study drug termination ("nontransfer patients"). RESULTS: The baseline characteristics of transfer and nontransfer patients were similar. Patients receiving eptifibatide were transferred less frequently than those receiving placebo (16% vs. 20%, p = 0.014). Transfer patients underwent more procedures and experienced a greater 30-day incidence of death or MI, as compared with nontransfer patients (21% vs. 12%, p = 0.001). Eptifibatide was associated with a reduction in death or MI through 30 days, independent of transfer status (2.5% absolute reduction), as well as for those transferred (5.5% absolute reduction). CONCLUSIONS: For patients with ACS admitted to community hospitals, eptifibatide is associated with a reduced need for transfer and improved clinical outcomes.

Duke Scholars

Published In

J Am Coll Cardiol

DOI

ISSN

0735-1097

Publication Date

February 2001

Volume

37

Issue

2

Start / End Page

492 / 498

Location

United States

Related Subject Headings

  • Survival Rate
  • Referral and Consultation
  • Platelet Aggregation Inhibitors
  • Peptides
  • Patient Transfer
  • Myocardial Revascularization
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Greenbaum, A. B., Harrington, R. A., Hudson, M. P., MacAulay, C. M., Wilcox, R. G., Simoons, M. L., … Ohman, E. M. (2001). Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. J Am Coll Cardiol, 37(2), 492–498. https://doi.org/10.1016/s0735-1097(00)01143-8
Greenbaum, A. B., R. A. Harrington, M. P. Hudson, C. M. MacAulay, R. G. Wilcox, M. L. Simoons, L. G. Berdan, et al. “Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.J Am Coll Cardiol 37, no. 2 (February 2001): 492–98. https://doi.org/10.1016/s0735-1097(00)01143-8.
Greenbaum AB, Harrington RA, Hudson MP, MacAulay CM, Wilcox RG, Simoons ML, et al. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. J Am Coll Cardiol. 2001 Feb;37(2):492–8.
Greenbaum, A. B., et al. “Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.J Am Coll Cardiol, vol. 37, no. 2, Feb. 2001, pp. 492–98. Pubmed, doi:10.1016/s0735-1097(00)01143-8.
Greenbaum AB, Harrington RA, Hudson MP, MacAulay CM, Wilcox RG, Simoons ML, Berdan LG, Guerci A, Cokkinos DV, Kitt MM, Lincoff AM, Topol EJ, Califf RM, Ohman EM. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. J Am Coll Cardiol. 2001 Feb;37(2):492–498.
Journal cover image

Published In

J Am Coll Cardiol

DOI

ISSN

0735-1097

Publication Date

February 2001

Volume

37

Issue

2

Start / End Page

492 / 498

Location

United States

Related Subject Headings

  • Survival Rate
  • Referral and Consultation
  • Platelet Aggregation Inhibitors
  • Peptides
  • Patient Transfer
  • Myocardial Revascularization
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans